Our desire to help patients drives everything we do at Visterra.
Clinical trials – research studies testing our therapeutic candidates in healthy subjects and patients – play a critically important part in developing our therapies. We design and run innovative and nimble pre-clinical studies and early phase clinical trials to answer critical questions about safety, tolerability, dosing regimen, pharmacokinetics, pharmacodynamics, biomarkers, and efficacy. We are thankful for and inspired by the volunteers and patients who participate in our trials.
Information about currently recruiting clinical trials of our therapeutic candidates is available below.
INDICATION
PROGRAM
NAME
TRIAL NUMBER
INDICATION
IgA nephropathy
PROGRAM
Sibeprenlimab (VIS649)
NAME
VISionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
TRIAL NUMBER
INDICATION
Autoimmune diseases
PROGRAM
VIS171
NAME
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
TRIAL NUMBER
INDICATION
Complement-mediated diseases
PROGRAM
VIS954
NAME
A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954
TRIAL NUMBER
